General Information of Drug (ID: DMJ63GW)

Drug Name
RPR-113829 Drug Info
Synonyms RPR-113829; CHEMBL48866; SCHEMBL8750304; BDBM50058204; (S)-2-{[6-((R)-2-Amino-3-mercapto-propylamino)-naphthalene-1-carbonyl]-amino}-4-methylsulfanyl-butyric acid
Cross-matching ID
PubChem CID
9953221
TTD Drug ID
DMJ63GW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lonafarnib DMGM2Z6 Hutchinson-Gilford progeria syndrome LD2B Approved [2]
Zarnestra DMF30HL Acute myeloid leukaemia 2A60 Phase 3 [3]
L-778123 DMWSC5L Lymphoma 2A80-2A86 Phase 1 [4]
GGTI-2418 DM8U23L Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
BMS214662 DM5M48F Non-small-cell lung cancer 2C25.Y Phase 1 [6]
L-745631 DM4UP7R Solid tumour/cancer 2A00-2F9Z Terminated [7]
ABT-839 DM4UN9A Non-small-cell lung cancer 2C25.Y Terminated [8]
MANUMYCIN A DM1SWOY N. A. N. A. Terminated [9]
SCH-44342 DMUL4VX N. A. N. A. Terminated [10]
RPR-114334 DMAIJT6 N. A. N. A. Terminated [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-745631 DM4UP7R Solid tumour/cancer 2A00-2F9Z Terminated [7]
ABT-839 DM4UN9A Non-small-cell lung cancer 2C25.Y Terminated [11]
MANUMYCIN A DM1SWOY N. A. N. A. Terminated [9]
SCH-44342 DMUL4VX N. A. N. A. Terminated [7]
RPR-114334 DMAIJT6 N. A. N. A. Terminated [1]
L-731735 DM1XBKC Solid tumour/cancer 2A00-2F9Z Terminated [7]
FUSIDIENOL DMI1Y92 N. A. N. A. Terminated [12]
ABT-100 DMPFLS5 Solid tumour/cancer 2A00-2F9Z Terminated [13]
B-956 DM1IO9X Solid tumour/cancer 2A00-2F9Z Terminated [14]
L-739749 DMAUG0L Solid tumour/cancer 2A00-2F9Z Terminated [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CAAX farnesyltransferase beta (FNTB) TT7WZIJ FNTB_HUMAN Inhibitor [1]
Farnesyl protein transferase (Ftase) TTXQKM3 FNTA_HUMAN; FNTB_HUMAN Inhibitor [1]

References

1 Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase. J Med Chem. 1997 Jun 6;40(12):1763-7.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
3 Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics. 2008 Sep;2(3):491-500.
4 Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein trans... Mol Cancer Ther. 2002 Jul;1(9):747-58.
5 Company report (Prescient)
6 Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia. 2004 Oct;18(10):1599-604.
7 Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
8 Aryl tetrahydropyridine inhibitors of farnesyltransferase: glycine, phenylalanine and histidine derivatives. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1359-62.
9 A novel metal-chelating inhibitor of protein farnesyltransferase. Bioorg Med Chem Lett. 2003 May 5;13(9):1523-6.
10 Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships. J Med Chem. 1999 Jun 17;42(12):2125-35.
11 Design and synthesis of o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase. Bioorg Med Chem Lett. 2005 Jan 3;15(1):153-8.
12 Modeling of binding modes and inhibition mechanism of some natural ligands of farnesyl transferase using molecular docking. J Med Chem. 2002 Mar 28;45(7):1460-5.
13 Potent farnesyltransferase inhibitor ABT-100 abrogates acute allograft rejection. J Heart Lung Transplant. 2005 Sep;24(9):1403-9.
14 Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 1995 Nov 15;55(22):5310-4.